Loomis, Sayles & Company
FOLD

Loomis, Sayles & Company’s Amicus Therapeutics FOLD Stock Holding History

Loomis, Sayles & Company’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,038,136
Closed -$24M – 855
2020
Q4 		$24M Buy
1,038,136
+124,196
+14% +$2.54M 0.03% 239
2020
Q3 		$12.9M Buy
+913,940
New +$13.3M 0.02% 284
2018
Q3 		– Sell
-401,694
Closed -$6.27M – 906
2018
Q2 		$6.27M Buy
401,694
+29,257
+8% +$442K 0.01% 506
2018
Q1 		$5.6M Buy
+372,437
New +$5.67M 0.01% 522
2015
Q4 		– Sell
-865,939
Closed -$12.1M – 1074
2015
Q3 		$12.1M Buy
865,939
+9,621
+1% +$151K 0.04% 402
2015
Q2 		$12.1M Buy
+856,318
New +$10.3M 0.03% 451

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company's FOLD Position: Q1 2021 in Review

Loomis, Sayles & Company sold out of Amicus Therapeutics (FOLD) in Q1 2021, closing a stake of 1,038,136 shares — an estimated $24M sold.

Loomis, Sayles & Company first reported a position in FOLD in Q2 2015 and held it in 6 quarters. The position peaked at $24M in Q4 2020. 259 funds tracked by Wall St. Rank hold FOLD as of Q1 2021.

  • Loomis, Sayles & Company reported no remaining Amicus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 1,038,136 Amicus Therapeutics shares in Q1 2021, an estimated $24M.
  • Loomis, Sayles & Company first reported a position in Amicus Therapeutics in Q2 2015 and held it in 6 quarters.
  • Loomis, Sayles & Company's Amicus Therapeutics position peaked at $24M in Q4 2020.
  • 259 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2021.

Based on Loomis, Sayles & Company's 13F filing for Q1 2021, filed 17 May 2021.